ZLAB Zai Lab Ltd

REDWOOD CITY, Calif., Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role ...

Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products The survival benefits for a new gastric cancer drug, bemarituzumab, were weaker than expected in the final analysis of a Phase Three trial

The final analysis of the Phase 3 trial showed reduced survival benefits from bemarituzumab. FORTITUDE-102 readout expected by late 2025 or early 2026 before regulatory filing. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special ) On Wednesday, Amgen Inc.

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 50 points on Thursday. Shares of C3.ai, Inc. AI fell sharply in the pre-market trading session after the company missed first-quarter earnings estimates and issued weak guidance.

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Friday. Shares of Netflix, Inc. NFLX fell in pre-market trading following second-quarter results. Netflix reported second-quarter revenue of $11.08 billion, up 16% year-over-year.